☆ 4.7 Meeting Abstract

Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE)

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

期刊

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

卷 105, 期 3, 页码 681-681

出版社

ELSEVIER SCIENCE INC

DOI: 10.1016/j.ijrobp.2019.08.031

关键词

-

类别

Oncology Radiology, Nuclear Medicine & Medical Imaging

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer

Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park

Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Stereotactic Ablative Radiation for Systemic Therapy-na?ve Oligometastatic Kidney Cancer

Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans Hammers, Waddah Arafat, Kevin Courtney, Isaac A. Bowman, David Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas

Summary: This study evaluated the feasibility of SAbR for patients with systemic therapy-naive oligometastatic RCC and found that SAbR can provide long-term disease control while preserving quality of life for patients.

EUROPEAN UROLOGY ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Matthew P. Deek, Kim Van der Eecken, Philip Sutera, Rebecca A. Deek, Valerie Fonteyne, Adrianna A. Mendes, Karel Decaestecker, Ana Ponce Kiess, Nicolaas Lumen, Ryan Phillips, Aurelie De Bruycker, Mark Mishra, Zaker Rana, Jason Molitoris, Bieke Lambert, Louke Delrue, Hailun Wang, Kathryn Lowe, Sofie Verbeke, Jo Van Dorpe, Renee Bultijnck, Geert Villeirs, Kathia De Man, Filip Ameye, Daniel Y. Song, Theodore DeWeese, Channing J. Paller, Felix Y. Feng, Alexander Wyatt, Kenneth J. Pienta, Maximillian Diehn, Soren M. Bentzen, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer, Emmanuel S. Antonarakis, Tamara L. Lotan, Alejandro Berlin, Shankar Siva, Piet Ost, Phuoc T. Tran

Summary: This study presents the long-term outcomes of metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) and investigates the impact of high-risk mutations on treatment outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer

Lily Chen, Bhavani S. Gannavarapu, Neil B. Desai, Michael R. Folkert, Michael Dohopolski, Ang Gao, Chul Ahn, Jeffrey Cadeddu, Aditya Bagrodia, Solomon Woldu, Ganesh V. Raj, Claus Roehrborn, Yair Lotan, Robert D. Timmerman, Aurelie Garant, Raquibul Hannan

Summary: This study analyzed the use of stereotactic ablative radiation (SAbR) at a dose of 45 Gy in 5 fractions for prostate cancer. The results showed promising safety profiles, but further prospective studies are needed to establish this dose regimen as standard of care.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

Davide Franceschini, Maria Ausilia Teriaca, Luca Dominici, Ciro Franzese, Marta Scorsetti

Summary: Oligometastatic patients are a heterogeneous group with only some benefiting from local ablative approaches like SABR. Identifying predictive and prognostic features is crucial for guiding clinical practice.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Article Oncology

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Anastasia Chalkidou, Thomas Macmillan, Mariusz T. Grzeda, Janet Peacock, Jennifer Summers, Saskia Eddy, Bola Coker, Hannah Patrick, Helen Powell, Lee Berry, Gareth Webster, Peter Ostler, Peter D. Dickinson, Matthew Q. Hatton, Ann Henry, Stephen Keevil, Maria A. Hawkins, Nick Slevin, Nicholas van As

Summary: Stereotactic ablative body radiotherapy (SABR) shows high overall survival and low toxicity in patients with extracranial oligometastatic cancer, providing evidence for its efficacy in this patient cohort.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer

N. Ari Wijetunga, Carlos H. dos Anjos, W. Iris Zhi, Mark Robson, C. Jillian Tsai, Yoshiya Yamada, Laura Dover, Erin F. Gillespie, Amy J. Xu, Jonathan T. Yang

Summary: The study found that long-term systemic disease control and survival can be achieved with SABR for oligometastatic breast cancer. Hormone receptor-positive patients with a long disease interval from initial diagnosis and limited systemic progression history may be ideal candidates for SABR to all sites of disease.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers

H. Greenwood, J. Hassan, K. Fife, T. V. Ajithkumar, K. Thippu Jayaprakash

Summary: Stereotactic ablative body radiotherapy (SABR) is a treatment method that delivers high doses of ionising radiation for various types of tumors. In this review, the efficacy of single-fraction SABR for different tumor types is analyzed, along with its advantages, disadvantages, and future directions.

CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial

Xianzhi Zhao, Tao Wang, Yusheng Ye, Jing Li, Xu Gao, Huojun Zhang

Summary: This study aims to investigate the impact of SBRT on oligometastatic hormone-sensitive PCa to delay the start of ADT. The research will be conducted in compliance with applicable local legislation and in accordance with the ethical principles developed by the World Medical Association in the Declaration of Helsinki 2013.

BMJ OPEN (2022)

添加到收藏夹

Article Oncology

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients

Ming-Wei Ma, Hong-Zhen Li, Xian-Shu Gao, Ming-Zhu Liu, Huan Yin, Kai-Wei Yang, Jia-Yan Chen, Xue-Ying Ren, Dian Wang

Summary: This retrospective study investigated the efficacy and prognostic factors of high-dose SABR for oligometastatic RCC patients. The results showed that high-dose SABR had a certain efficacy in this patient population, and patients with a short time interval between radiation therapy and those who received radiation therapy before tyrosine kinase inhibitor (TKI) failure had a better survival period.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer

Abhishek Kumar, Christopher Straka, Patrick T. Courtney, Lucas Vitzthum, Paul Riviere, James D. Murphy

Summary: The study examined the cost-effectiveness of adding Stereotactic Ablative Radiation therapy (SABR) to standard therapy for cancer patients with oligometastatic disease. Results showed that although the addition of SABR increased costs, it improved quality adjusted survival, making it a cost-effective treatment option.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC

Serena Badellino, Mario Levis, Erica Maria Cuffini, Marzia Cerrato, Erika Orlandi, Ilaria Chiovatero, Arianna Aprile, Alessio Gastino, Chiara Cavallin, Giuseppe Carlo Iorio, Ramona Parise, Cristina Mantovani, Umberto Ricardi

Summary: Local ablative therapy (LAT) has been incorporated into guidelines for the management of oligometastatic non-small cell lung cancer (NSCLC) and has shown significant benefits. This study evaluates the role of LAT in non-oncogene addicted oligometastatic NSCLC patients and reports the clinical outcomes of the largest retrospective series to date.

CANCERS (2022)

添加到收藏夹

Article Oncology

Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC

Sean All, Aurelie Garant, Raquibul Hannan

Summary: Recent data suggests that a subgroup of mRCC patients with oligometastatic disease may benefit from aggressive local therapy, with the potential of high local control efficacy and improved survival using SAbR. Large prospective trials are needed to integrate SAbR with systemic therapies to harness the optimal benefit for this patient population.

SEMINARS IN RADIATION ONCOLOGY (2021)

添加到收藏夹

Review Oncology

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma

Andrew B. Barbour, Simon Kirste, Anca-Liga Grosu, Shankar Siva, Alexander V. Louie, Hiroshi Onishi, Anand Swaminath, Bin S. Teh, Sarah P. Psutka, Emily S. Weg, Jonathan J. J. Chen, Jing Zeng, John L. Gore, Evan Hall, Jay J. J. Liao, Rohann J. M. Correa, Simon S. Lo

Summary: Patients with localized renal cell carcinoma often have medical comorbidities limiting their surgical candidacy, thus necessitating less invasive treatment options. Stereotactic ablative radiotherapy has emerged as a safe and effective management option with a growing body of evidence supporting its use. This article discusses recent advances in the use of stereotactic ablation radiotherapy for localized renal cell carcinoma, while guiding providers on practical points for patient selection and clinical application.

CANCERS (2023)

添加到收藏夹

Review Oncology

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer A Systematic Review and Meta-analysis

Eric J. Lehrer, Raj Singh, Ming Wang, Vernon M. Chinchilli, Daniel M. Trifiletti, Piet Ost, Shankar Siva, Mao-bin Meng, Leila Tchelebi, Nicholas G. Zaorsky

Summary: The meta-analysis shows that stereotactic ablative radiotherapy is relatively safe and clinically beneficial in patients with oligometastatic cancer, with low rates of toxic effects and acceptable survival rates. Further research is needed to validate these findings.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Education, Scientific Disciplines

Establishing a Deaf and American Sign Language Inclusive Residency Program

Colin Hill, Curtiland Deville, Ana Kiess, Amol Narang, Tilak Ratnanather, Jessica Bienstock, Loring Brinckerhoff, Aaron Hodukavich, Roberta Anderson, Sara Alcorn, Theodore DeWeese, Akila Viswanathan, Brandi R. Page

Summary: This article reports on the development of a Deaf and American Sign Language (ASL) inclusive residency program and provides a model for creating accessible training programs for Deaf physicians and other trainees with disabilities.

ACADEMIC MEDICINE (2022)

添加到收藏夹

Article Oncology

A Survey to Assess and Delineate Approaches to Medical Student Outreach to Promote Diversity at Academic Radiation Oncology Programs

Malcolm D. Mattes, Curtiland Deville

Summary: Most academic radiation oncology departments do not offer educational outreach targeting women or minority students or promote programs specifically designed for them, indicating the need for further efforts to attract a more diverse workforce.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Meeting Abstract Oncology

Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.

Emerson Lee, Tanmay Singh, Misop Han, Curtiland Deville, Aditya Halthore, Stephen C. Greco, Phuoc T. Tran, Theodore L. DeWeese, Danny Song

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?

Yilin Cao, Daniel Y. Song, Curtiland Deville, Theodore L. DeWeese, Stephen Greco, Phuoc T. Tran, Matthew P. Deek

Summary: This study investigated the rate of prostate bed recurrence in oligometastatic prostate cancer patients after metastasis-directed therapy. The results showed that patients who did not receive prostate bed irradiation had a higher rate of local failure. Prospective studies are needed to determine when prostate bed irradiation should be considered for patients with oligometastatic prostate cancer after radical prostatectomy.

PROSTATE (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

A Medicare Claims Analysis of Racial and Ethnic Disparities in the Access to Radiation Therapy Services

Constantine A. Mantz, Nikhil G. Thaker, Curtiland Deville, Anne Hubbard, Praveen Pendyala, Najeeb Mohideen, Vivek Kavadi, Karen M. Winkfield

Summary: This study examines healthcare disparities in radiation therapy among different racial and ethnic groups in the USA. The results show that Black, Hispanic, and Native American patients have higher rates of failure to initiate treatment, and among those who do initiate treatment, Black and Hispanic patients require a longer time for treatment completion. These findings provide opportunities to address healthcare inequalities.

JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES (2023)

添加到收藏夹

Article Oncology

Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease

Shivanshu Awasthi, G. Daniel Grass, Javier Torres-Roca, Peter A. S. Johnstone, Julio Pow-Sang, Jasreman Dhillon, Jong Park, Robert J. Rounbehler, Elai Davicioni, Alex Hakansson, Yang Liu, Angelina K. Fink, Amanda DeRenzis, Jordan H. Creed, Michael Poch, Roger Li, Brandon Manley, Daniel Fernandez, Arash Naghavi, Kenneth Gage, Grace Lu-Yao, Evangelia Katsoulakis, Ryan J. Burri, Andrew Leone, Cesar E. Ercole, Joshua D. Palmer, Neha Vapiwala, Curtiland Deville, Timothy R. Rebbeck, Adam P. Dicker, William Kelly, Kosj Yamoah

Summary: This study finds that African American men with prostate cancer have a higher risk of genetic risk reclassification compared to non-African American men. Integrating genomic classifiers with clinical risk classification can help identify African American men with localized prostate cancer who have a high genomic risk of early metastatic disease.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy

Emerson E. Lee, Tanmay Singh, Chen Hu, Misop Han, Curtiland Deville, Aditya Halthore, Stephen Greco, Phuoc Tran, Theodore DeWeese, Daniel Y. Song

Summary: This study found that initiating salvage radiation therapy (SRT) when PSA levels are below 0.5 ng/ml is associated with improved metastasis-free survival (MFS) in patients with biochemical recurrence. Seminal vesicle invasion is also associated with shorter time to biochemical failure and eventual metastasis.

PROSTATE (2023)

添加到收藏夹

Editorial Material Oncology

Ensuring That Health Inequities and Disparities Are Not Exacerbated in the Evolving Oligometastatic Treatment Paradigm

Sara R. Alcorn, Curtiland Deville

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality

Edward Christopher Dee, Neil K. Taunk, Fumiko L. Chino, Curtiland Deville, Shearwood McClelland, Vinayak Muralidhar, Sean N. McBride, Erin F. Gillespie, Kosj Yamoah, Paul L. Nguyen, Brandon A. Mahal, Karen M. Winkfield, Neha Vapiwala, Patricia Mae G. Santos

Summary: Shorter radiation regimens may reduce treatment noncompletion rates, but black patients are consistently less likely to receive them for breast cancer and prostate cancer. However, evidence suggests that these shorter regimens could lead to similar oncologic outcomes.

JCO ONCOLOGY PRACTICE (2023)

添加到收藏夹

Article Oncology

In silico comparison of whole pelvis intensity-modulated photon versus proton therapy for the postoperative management of prostate cancer

Emile Gogineni, Ian K. Cruickshank, Hao Chen, Aditya Halthore, Heng Li, Curtiland Deville

Summary: This study compared intensity-modulated photon (IMRT) and proton (IMPT) radiation therapy for treating prostate cancer in the postoperative setting. It was found that IMPT significantly reduced dose to organs at risk (OARs) while achieving comparable target coverage to IMRT.

ACTA ONCOLOGICA (2023)

添加到收藏夹

Editorial Material Oncology

Perspectives on Diversity and Inclusion in Radiation Oncology: A Decade Later

Curtiland Deville Jr

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Editorial Material Oncology

The Path Forward Toward Health Equity in Radiation Oncology in a Post-2020 Era

Curtiland Deville Jr

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

添加到收藏夹

Meeting Abstract Health Care Sciences & Services

Palliative Radiotherapy Deserts: Impact of Race, Poverty, the Rural-Urban Continuum, and Radiotherapy Resource Density on Late-Stage Prostate Cancer

Anna Lavigne, Theodore DeWeese, Jean Wright, Srinivasan Yegnasubramanian, Curtiland Deville, Thomas Smith, Sara Alcorn

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2022)

添加到收藏夹

Article Oncology

Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer

Diane K. Reyes, Bruce J. Trock, Phuoc T. Tran, Christian P. Pavlovich, Curtiland Deville, Mohamad E. Allaf, Stephen C. Greco, Daniel Y. Song, Trinity J. Bivalacqua, Misop Han, Alan W. Partin, A. Oliver Sartor, Steven P. Rowe, Kenneth J. Pienta

Summary: The study investigated the use of multimodal therapies for men with newly diagnosed, synchronous, oligometastatic prostate cancer. The results showed promising outcomes and suggest that this approach could be a new treatment method for patients with this type of cancer.

MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy

Alicia Bao, Andrew R. Barsky, Russell Maxwell, Justin E. Bekelman, Stefan Both, John P. Christodouleas, Curtiland Deville, Penny Fang, Zelig A. Tochner, Neha Vapiwala

Summary: This study retrospectively assessed the long-term disease control outcomes of 166 favorable risk PC patients who received PBT, with the majority having low-risk disease. The 5- and 8-year BFFS rates were 97% and 92%, respectively, showing similar or improved results compared to previous studies with other treatment modalities for localized intact PC.

INTERNATIONAL JOURNAL OF PARTICLE THERAPY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.